AMMONIA N 13
Post-LOEANDAINTRAVENOUSINJECTABLE
Approved
Apr 2015
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AMMONIA N 13 by Sofie is 13 injection is a radiolabeled analog of ammonia that is distributed to all organs of the body after intravenous administration. First approved in 2015.
Drug data last refreshed 21h ago
Mechanism of Action
13 Injection is a radiolabeled analog of ammonia that is distributed to all organs of the body after intravenous administration. It is extracted from the blood in the coronary capillaries into the myocardial cells where it is metabolized to glutamine N 13 and retained in the cells. The presence of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Sofie
Worked on AMMONIA N 13 at Sofie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.